{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T20:38:41Z","timestamp":1782160721154,"version":"3.54.5"},"reference-count":106,"publisher":"FapUNIFESP (SciELO)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:p>Glucocorticoid-induced osteoporosis (GIO) is the most common form of secondary osteoporosis. Fractures, which are often asymptomatic, may occur in as many as 30_50% of patients receiving chronic glucocorticoid therapy. Vertebral fractures occur early after exposure to glucocorticoids, at a time when bone mineral density (BMD) declines rapidly. Fractures tend to occur at higher BMD levels than in women with postmenopausal osteoporosis. Glucocorticoids have direct and indirect effects on the skeleton. They impair the replication, differentiation, and function of osteoblasts and induce the apoptosis of mature osteoblasts and osteocytes. These effects lead to a suppression of bone formation, a central feature in the pathogenesis of GIO. Glucocorticoids also favor osteoclastogenesis and as a consequence increase bone resorption. Bisphosphonates are the most effective of the various therapies that have been assessed for the management of GIO. Anabolic therapeutic strategies are under investigation. Teriparatide seems to be also efficacious for the treatment of patients with GIO.<\/jats:p>","DOI":"10.1590\/s0004-27302007000800028","type":"journal-article","created":{"date-parts":[[2008,1,18]],"date-time":"2008-01-18T08:17:16Z","timestamp":1200644236000},"page":"1404-1412","source":"Crossref","is-referenced-by-count":29,"title":["Glucocorticoid-Induced osteoporosis: clinical and therapeutic aspects"],"prefix":"10.1590","volume":"51","author":[{"given":"Gherardo","family":"Mazziotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Canalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.tem.2006.03.009","article-title":"Glucocorticoid-induced osteoporosis: an update","volume":"7","author":"Mazziotti G","year":"2006","journal-title":"Trends Endocrinol Metab"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11926-007-0026-x","article-title":"Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis","volume":"9","author":"Compston JE","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.bone.2003.11.026","article-title":"Perspectives on glucocorticoid-induced osteoporosis","volume":"34","author":"Canalis E","year":"2004","journal-title":"Bone","ISSN":"https:\/\/id.crossref.org\/issn\/8756-3282","issn-type":"print"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1210\/endo.140.10.7034","article-title":"Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis","volume":"140","author":"Hofbauer LC","year":"1999","journal-title":"Endocrinology","ISSN":"https:\/\/id.crossref.org\/issn\/0013-7227","issn-type":"print"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/endo.139.3.5778","article-title":"Dexamethasone promotes expression of membrane- bound macrophage colony-stimulating factor in murine osteoblast-like cells","volume":"139","author":"Rubin J","year":"1998","journal-title":"Endocrinology","ISSN":"https:\/\/id.crossref.org\/issn\/0013-7227","issn-type":"print"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1530\/eje.1.02147","article-title":"High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption","volume":"154","author":"Dovio A","year":"2006","journal-title":"Eur J Endocrinol","ISSN":"https:\/\/id.crossref.org\/issn\/0804-4643","issn-type":"print"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","article-title":"Glucocorti coid-induced osteoporosis: pathophysiology and therapy","volume":"18","author":"Canalis E","year":"2007","journal-title":"Osteoporos Int","ISSN":"https:\/\/id.crossref.org\/issn\/0937-941X","issn-type":"print"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11914-005-0017-7","article-title":"Mechanisms of glucocorticoid action in bone","volume":"3","author":"Canalis E","year":"2005","journal-title":"Curr Osteoporos Rep"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bbrc.2005.01.117","article-title":"Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts","volume":"329","author":"Ohnaka K","year":"2005","journal-title":"Biochem Biophys Res Commun","ISSN":"https:\/\/id.crossref.org\/issn\/0006-291X","issn-type":"print"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1359\/jbmr.2003.18.7.1186","article-title":"Bone morphogenetic protein-2 restores mineralization in glucocorticoid-inhibited MC3T3-E1 osteoblast cultures","volume":"18","author":"Luppen CA","year":"2003","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11154-006-9000-6","article-title":"Bone morphogenetic proteins and their antagonists","volume":"7","author":"Gazzerro E","year":"2006","journal-title":"Rev Endocr Metab Disord"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/jcb.240570314","article-title":"Cortisol down regulates osteoblast alpha 1(I) procollagen mRNA by transcriptional and post-transcriptional mechanisms","volume":"57","author":"Delany AM","year":"1995","journal-title":"J Cell Biochem","ISSN":"https:\/\/id.crossref.org\/issn\/0730-2312","issn-type":"print"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1359\/JBMR.0301242","article-title":"Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k","volume":"19","author":"Liu Y","year":"2004","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1359\/JBMR.051103","article-title":"Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice","volume":"21","author":"Lane NE","year":"2006","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1172\/JCI113885","article-title":"Insulin-like growth factor I mediates selected anabolic effects of parathyroid hormone in bone cultures","volume":"83","author":"Canalis E","year":"1989","journal-title":"J Clin Invest","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9738","issn-type":"print"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","article-title":"Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial","volume":"102","author":"Lane NE","year":"1998","journal-title":"J Clin Invest","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9738","issn-type":"print"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"26607","DOI":"10.1074\/jbc.270.44.26607","article-title":"Cortisol increases interstitial collagenase expression in osteoblasts by post-transcriptional mechanisms","volume":"270","author":"Delany AM","year":"1995","journal-title":"J Biol Chem","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9258","issn-type":"print"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1210\/jc.2002-012101","article-title":"The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence","volume":"87","author":"Rubin MR","year":"2002","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1530\/eje.1.01841","article-title":"Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects","volume":"152","author":"Bonadonna S","year":"2005","journal-title":"Eur J Endocrinol","ISSN":"https:\/\/id.crossref.org\/issn\/0804-4643","issn-type":"print"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.metabol.2006.01.009","article-title":"Active acromegaly enhances spontaneous parathyroid hormone pulsatility","volume":"55","author":"Mazziotti G","year":"2006","journal-title":"Metabolism","ISSN":"https:\/\/id.crossref.org\/issn\/0026-0495","issn-type":"print"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1359\/jbmr.1997.12.4.616","article-title":"Episodic secretion of parathyroid hormone in post-menopausal women: assessment by deconvolution analysis and approximate entropy","volume":"12","author":"Samuels MH","year":"1997","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1210\/endo.134.1.8275958","article-title":"Regulation of parathyroid hormone (PTH)\/PTHrelated peptide receptor messenger ribonucleic acid by glucocorticoids and PTH in ROS 17\/2.8 and OK cells","volume":"134","author":"Urena P","year":"1994","journal-title":"Endocrinology","ISSN":"https:\/\/id.crossref.org\/issn\/0013-7227","issn-type":"print"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00675619","article-title":"Differential effects of glucocorticoids on corti cal appendicular and cortical vertebral bone mineral content","volume":"52","author":"Laan RF","year":"1993","journal-title":"Calcif Tissue Int","ISSN":"https:\/\/id.crossref.org\/issn\/0171-967X","issn-type":"print"},{"key":"ref24","first-page":"1301","article-title":"Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy","volume":"74","author":"Giustina A","year":"1992","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1378\/chest.127.2.515","article-title":"Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment","volume":"127","author":"Malerba M","year":"2005","journal-title":"Chest","ISSN":"https:\/\/id.crossref.org\/issn\/0012-3692","issn-type":"print"},{"key":"ref26","first-page":"122","article-title":"Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone","volume":"80","author":"Giustina A","year":"1995","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000061083","article-title":"Growth hormone in glucocorticoid-induced osteoporosis","volume":"30","author":"Manelli F","year":"2002","journal-title":"Front Horm Res","ISSN":"https:\/\/id.crossref.org\/issn\/0301-3073","issn-type":"print"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1183\/09031936.00074905","article-title":"Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma","volume":"28","author":"Derendorf H","year":"2006","journal-title":"Eur Respir J","ISSN":"https:\/\/id.crossref.org\/issn\/0903-1936","issn-type":"print"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1677\/joe.0.1620259","article-title":"Effects of IGF-1 combined with GH on glucocorticoid-induced changes of bone and connective tissue turnover in man","volume":"162","author":"Berneis K","year":"1999","journal-title":"J Endocrinol","ISSN":"https:\/\/id.crossref.org\/issn\/0022-0795","issn-type":"print"},{"issue":"7","key":"ref30","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1210\/jc.2006-2877","article-title":"Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: 3-year randomized study","volume":"92","author":"Simon D","year":"2007","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref31","first-page":"2492","article-title":"Effects on growth and body composition of growth hormone treatment in children with juvenile idiopathic arthritis requiring steroid therapy","volume":"30","author":"Simon D","year":"2003","journal-title":"J Rheumatol","ISSN":"https:\/\/id.crossref.org\/issn\/0315-162X","issn-type":"print"},{"key":"ref32","first-page":"1407","article-title":"Bone mass development and bone metabolism in juvenile idiopathic arthritis: treatment with growth hormone for 4 years","volume":"31","author":"Bechtold S","year":"2004","journal-title":"J Rheumatol","ISSN":"https:\/\/id.crossref.org\/issn\/0315-162X","issn-type":"print"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1210\/jc.2004-1603","article-title":"Growth hormone changes bone geometry and body composition in patients with juvenile idiopathic arthritis requiring glucocorticoid treatment: a controlled study using peripheral quantitative computed tomography","volume":"90","author":"Bechtold S","year":"2005","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00223-006-0019-1","article-title":"The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis","volume":"79","author":"van Staa TP","year":"2006","journal-title":"Calcif Tissue Int","ISSN":"https:\/\/id.crossref.org\/issn\/0171-967X","issn-type":"print"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a metaanalysis","volume":"13","author":"van Staa TP","year":"2002","journal-title":"Osteoporos Int","ISSN":"https:\/\/id.crossref.org\/issn\/0937-941X","issn-type":"print"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00198-003-1548-3","article-title":"Oral glucocorticoid use is associated with an increased risk of fracture","volume":"15","author":"Steinbuch M","year":"2004","journal-title":"Osteoporos Int","ISSN":"https:\/\/id.crossref.org\/issn\/0937-941X","issn-type":"print"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ecl.2005.01.014","article-title":"Osteoporosis associated with excess glucocorticoids","volume":"34","author":"Shaker JL","year":"2005","journal-title":"Endocrinol Metab Clin North Am","ISSN":"https:\/\/id.crossref.org\/issn\/0889-8529","issn-type":"print"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bone.2006.02.005","article-title":"High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study","volume":"39","author":"Angeli A","year":"2006","journal-title":"Bone","ISSN":"https:\/\/id.crossref.org\/issn\/8756-3282","issn-type":"print"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00198-003-1426-z","article-title":"Osteoporosis after solid organ and bone marrow transplantation","volume":"14","author":"Cohen A","year":"2003","journal-title":"Osteoporos Int","ISSN":"https:\/\/id.crossref.org\/issn\/0937-941X","issn-type":"print"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2796.2005.01467.x","article-title":"Fracture risk associated with systemic and topical corticosteroids","volume":"257","author":"Vestergaard P","year":"2005","journal-title":"J Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0954-6820","issn-type":"print"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.2001.16.3.581","article-title":"Use of inhaled corticosteroids and risk of fractures","volume":"3","author":"van Staa TP","year":"2001","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1164\/rccm.200206-606OC","article-title":"Inhaled corticosteroids and hip fracture: a population- based case-control study","volume":"166","author":"Hubbard RB","year":"2002","journal-title":"Am J Respir Crit Care Med","ISSN":"https:\/\/id.crossref.org\/issn\/1073-449X","issn-type":"print"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM200202143460716","article-title":"Bone loss and inhaled glucocorticoids","volume":"346","author":"van Staa TP","year":"2002","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1056\/NEJMoa002304","article-title":"Effects of inhaled glucocorticoids on bone density in premenopausal women","volume":"345","author":"Israel E","year":"2001","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2796.2006.01754.x","article-title":"Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip\/femur fracture: a population-based case-control study","volume":"261","author":"de Vries F","year":"2007","journal-title":"J Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0954-6820","issn-type":"print"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1080\/00365520600664276","article-title":"Skeletal morbidity in inflammatory bowel disease","volume":"243","author":"van Hogezand RA","year":"2006","journal-title":"Scand J Gastroenterol","ISSN":"https:\/\/id.crossref.org\/issn\/0036-5521","issn-type":"print"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.berh.2005.06.008","article-title":"Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates","volume":"19","author":"Romas E","year":"2005","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s001980200097","article-title":"An association between respiratory function and bone mineral density in women from the general community: a cross sectional study","volume":"13","author":"Lekamwasam S","year":"2002","journal-title":"Osteoporos Int","ISSN":"https:\/\/id.crossref.org\/issn\/0937-941X","issn-type":"print"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0002-9343(02)01297-4","article-title":"The risk of osteoporosis in Cau casian men and women with obstructive airways disease","volume":"114","author":"Sin DD","year":"2003","journal-title":"Am J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9343","issn-type":"print"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1210\/jc.2005-0646","article-title":"Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid- regulated gene expression","volume":"90","author":"Russcher H","year":"2005","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1210\/jc.2003-031422","article-title":"The ER22\/23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition and muscle strength in young adults","volume":"89","author":"van Rossum EF","year":"2004","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1210\/er.2003-0031","article-title":"11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response","volume":"25","author":"Tomlinson JW","year":"2004","journal-title":"Endocr Rev","ISSN":"https:\/\/id.crossref.org\/issn\/0163-769X","issn-type":"print"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1359\/jbmr.2001.16.6.1037","article-title":"Modulation of 11\u00e2-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation","volume":"16","author":"Cooper MS","year":"2001","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"30232","DOI":"10.1074\/jbc.M001286200","article-title":"C\/EBP regulates hepatic transcription of 11beta- hydroxysteroid dehydrogenase type 1: A novel mechanism for cross-talk between the C\/EBP and glucocorticoid signaling pathways","volume":"275","author":"Williams LJ","year":"2000","journal-title":"J Biol Chem","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9258","issn-type":"print"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1359\/jbmr.2002.17.6.979","article-title":"Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure","volume":"17","author":"Cooper MS","year":"2002","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1007\/s00198-005-2016-z","article-title":"Practice patterns in patients at risk for glucocorticoid-induced osteoporosis","volume":"16","author":"Feldstein AC","year":"2005","journal-title":"Osteoporos Int","ISSN":"https:\/\/id.crossref.org\/issn\/0937-941X","issn-type":"print"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.rhu.0000242778.65766.22","article-title":"Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men","volume":"12","author":"Cruse LM","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s10067-006-0406-z","article-title":"Osteoporosis in men: are we referring enough for DXA and how?","volume":"26","author":"Al Attia H","year":"2007","journal-title":"Clin Rheumatol","ISSN":"https:\/\/id.crossref.org\/issn\/0770-3198","issn-type":"print"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11926-007-0025-y","article-title":"Osteoporosis in men: pathophysiology and treatment","volume":"9","author":"Gennari L","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/art.22350","article-title":"Osteoporosis management in patients with rheumatoid arthritis: Evidence for improvement","volume":"55","author":"Solomon DH","year":"2006","journal-title":"Arthritis Rheum","ISSN":"https:\/\/id.crossref.org\/issn\/0004-3591","issn-type":"print"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/art.20403","article-title":"Multifaceted intervention to improve rheumatologists' management of glucocorticoid-induced osteoporosis: a randomized controlled trial","volume":"51","author":"Solomon DH","year":"2004","journal-title":"Arthritis Rheum","ISSN":"https:\/\/id.crossref.org\/issn\/0004-3591","issn-type":"print"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archinte.167.6.591","article-title":"Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial","volume":"167","author":"Curtis JR","year":"2007","journal-title":"Arch Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9926","issn-type":"print"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5","article-title":"Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis","volume":"44","year":"2001","journal-title":"Arthritis Rheum","ISSN":"https:\/\/id.crossref.org\/issn\/0004-3591","issn-type":"print"},{"key":"ref64","series-title":"Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment","year":"2002"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11926-004-0085-1","article-title":"US and UK guidelines for glucocorticoid- induced osteoporosis: similarities and differences","volume":"6","author":"Compston J","year":"2004","journal-title":"Curr Rheumatol Rep"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1185\/030079903125003062","article-title":"Is bone mineral density predictive of fracture risk reduction?","volume":"20","author":"Cefalu CA","year":"2004","journal-title":"Curr Med Res Opin","ISSN":"https:\/\/id.crossref.org\/issn\/0300-7995","issn-type":"print"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1359\/jbmr.1997.12.11.1883","article-title":"Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study","volume":"12","author":"Lunt M","year":"1997","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1359\/jbmr.2000.15.7.1368","article-title":"Bone structure in patients with low bone mineral density with or without vertebral fractures","volume":"15","author":"Oleksik A","year":"2000","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11914-006-0004-7","article-title":"Clinical utility of microarchitecture measurements of trabecular bone","volume":"4","author":"Carballido-Gamio J","year":"2006","journal-title":"Curr Osteoporos Rep"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1359\/JBMR.050603","article-title":"Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women","volume":"20","author":"Bonadonna S","year":"2005","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1359\/jbmr.060112","article-title":"Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy","volume":"21","author":"Mazziotti G","year":"2006","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","article-title":"Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis","volume":"18","author":"Vestergaard P","year":"2007","journal-title":"Osteoporos Int","ISSN":"https:\/\/id.crossref.org\/issn\/0937-941X","issn-type":"print"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/jbmr.5650050705","article-title":"Ascertainment of risk factors for osteoporosis: comparison of interview data with medical record review","volume":"5","author":"Beard CM","year":"1990","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1007\/s00586-003-0613-0","article-title":"Recognizing and reporting osteoporotic vertebral fractures","volume":"12","author":"Grigoryan M","year":"2003","journal-title":"Eur Spine J","ISSN":"https:\/\/id.crossref.org\/issn\/0940-6719","issn-type":"print"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study","volume":"11","author":"Garnero P","year":"1996","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"issue":"5","key":"ref76","first-page":"1051","article-title":"Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium home-ostasis","volume":"34","author":"Jacobs JW","year":"2007","journal-title":"J Rheumatol","ISSN":"https:\/\/id.crossref.org\/issn\/0315-162X","issn-type":"print"},{"issue":"7","key":"ref77","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta11070","article-title":"Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis","volume":"11","author":"Kanis JA","year":"2007","journal-title":"Health Technol Assess","ISSN":"https:\/\/id.crossref.org\/issn\/1366-5278","issn-type":"print"},{"issue":"3","key":"ref78","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/rheumatology\/kel249","article-title":"Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucorticoids","volume":"46","author":"van Staa TP","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/jme.17.4.185","article-title":"Unprincipled QALYs: a response to Cubbon","volume":"17","author":"Harris J","year":"1991","journal-title":"J Med Ethics","ISSN":"https:\/\/id.crossref.org\/issn\/0306-6800","issn-type":"print"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1359\/jbmr.2002.17.8.1512","article-title":"The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression","volume":"17","author":"Amin S","year":"2002","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMoa053569","article-title":"STOP Investigators: Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis","volume":"355","author":"de Nijs RN","year":"2006","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis: Glucocorticoid-Induced Osteoporosis Intervention Study Group","volume":"339","author":"Saag KG","year":"1998","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double- blind, placebo-controlled, parallel-group study","volume":"42","author":"Cohen S","year":"1999","journal-title":"Arthritis Rheum","ISSN":"https:\/\/id.crossref.org\/issn\/0004-3591","issn-type":"print"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"67","author":"Wallach S","year":"2000","journal-title":"Calcif Tissue Int","ISSN":"https:\/\/id.crossref.org\/issn\/0171-967X","issn-type":"print"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study","volume":"15","author":"Reid DM","year":"2000","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","article-title":"Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial","volume":"44","author":"Adachi JD","year":"2001","journal-title":"Arthritis Rheum","ISSN":"https:\/\/id.crossref.org\/issn\/0004-3591","issn-type":"print"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1359\/jbmr.2003.18.5.919","article-title":"Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium","volume":"18","author":"Sambrook PN","year":"2003","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/thx.2003.013839","article-title":"Research Committee of the British Thoracic Society: Research Committee of the British Thoracic Society. Five- year study of etidronate and\/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and\/or inhaled glucocorticoids","volume":"59","author":"Campbell IA","year":"2004","journal-title":"Thorax","ISSN":"https:\/\/id.crossref.org\/issn\/0040-6376","issn-type":"print"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJMoa035617","article-title":"Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation","volume":"350","author":"Shane E","year":"2004","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1210\/en.2006-0539","article-title":"Myostatin gene deletion prevents glucocorticoid- induced muscle atrophy","volume":"148","author":"Gilson H","year":"2007","journal-title":"Endocrinology","ISSN":"https:\/\/id.crossref.org\/issn\/0013-7227","issn-type":"print"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2796.2006.01655.x","article-title":"Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update","volume":"259","author":"Boonen S","year":"2006","journal-title":"J Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0954-6820","issn-type":"print"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1359\/jbmr.2000.15.4.770","article-title":"Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen","volume":"15","author":"Shiraishi A","year":"2000","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s002239900705","article-title":"Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol","volume":"65","author":"Schacht E","year":"1999","journal-title":"Calcif Tissue Int","ISSN":"https:\/\/id.crossref.org\/issn\/0171-967X","issn-type":"print"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"961","DOI":"10.7326\/0003-4819-125-12-199612150-00004","article-title":"Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled trial","volume":"125","author":"Buckley LM","year":"1996","journal-title":"Ann Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"issue":"1-2","key":"ref95","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsbmb.2005.06.020","article-title":"The Vitamin D requirement in health and disease","volume":"97","author":"Heaney RP","year":"2005","journal-title":"J Steroid Biochem Mol Biol","ISSN":"https:\/\/id.crossref.org\/issn\/0960-0760","issn-type":"print"},{"issue":"3","key":"ref96","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.bone.2006.10.019","article-title":"Ibandronate treatment reverses glucocorticoid-induced loss of bone mineral density and strength in minipigs","volume":"40","author":"Gluer CC","year":"2007","journal-title":"Bone","ISSN":"https:\/\/id.crossref.org\/issn\/8756-3282","issn-type":"print"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10495-005-1893-0","article-title":"Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis","volume":"10","author":"Gu G","year":"2005","journal-title":"Apoptosis","ISSN":"https:\/\/id.crossref.org\/issn\/1360-8185","issn-type":"print"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S1568-9972(03)00056-9","article-title":"Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease","volume":"4","author":"Franchimont N","year":"2003","journal-title":"Autoimmun Rev"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone","volume":"104","author":"Jilka RL","year":"1999","journal-title":"J Clin Invest","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9738","issn-type":"print"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00774-005-0627-2","article-title":"Low- dose parathyroid hormone and estrogen reverse alkaline phosphatase activity suppressed by dexamethasone in mouse osteoblastic","volume":"23","author":"Iu MF","year":"2005","journal-title":"J Bone Miner Metab"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nature02040","article-title":"Osteoblastic cells regulate the haematopoietic stem cell niche","volume":"425","author":"Calvi LM","year":"2003","journal-title":"Nature","ISSN":"https:\/\/id.crossref.org\/issn\/0028-0836","issn-type":"print"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","article-title":"Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: Results of a randomized controlled clinical trial","volume":"102","author":"Lane NE","year":"1998","journal-title":"J Clin Invest","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9738","issn-type":"print"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s001980070111","article-title":"Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis","volume":"11","author":"Lane NE","year":"2000","journal-title":"Osteoporos Int","ISSN":"https:\/\/id.crossref.org\/issn\/0937-941X","issn-type":"print"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00198-002-1312-0","article-title":"Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis","volume":"14","author":"Rehman Q","year":"2003","journal-title":"Osteoporos Int","ISSN":"https:\/\/id.crossref.org\/issn\/0937-941X","issn-type":"print"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1210\/jc.2003-032066","article-title":"Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34)","volume":"89","author":"Buxton EC","year":"2004","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jocd.2007.03.075","article-title":")( Active comparator trial of teriparatide versus alendronate in the treatment of glucocorticoid-induced osteoporosis","volume":"10","author":"Taylor KA","year":"2007","journal-title":"J Clin Densitom"}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v51n8\/26.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T22:39:47Z","timestamp":1495751987000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302007000800028&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":106,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S0004-27302007000800028"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302007000800028","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}